

These COVID-19 Stocks are Still “Strong Buy” Opportunities

Some of the top biotech companies are now in human trials, and seeing a good deal of progress. Better, as we near better and better results from these companies, their stocks are still exploding to higher highs.

Top Stock No. 1 – Inovio Pharmaceuticals (INO)

We recommended Inovio Pharmaceuticals on April 15, as it traded at just \$7. Then, just last Wednesday, we highlighted it again as an opportunity at \$13.55. As of this morning, INO is up to \$13.80 and is still an opportunity.



To date, preclinical data has shown promising immune responses across animal models. "Preclinical results for INOVIO's COVID vaccine have been consistent with completed Phase 1 vaccine study for Middle East Respiratory Syndrome (MERS), also caused by a coronavirus, in which INOVIO's DNA vaccine was well tolerated and induced high levels of antibody responses in 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants," notes Inovio.

H.C. Wainwright for example has a buy rating on the stock with a target of \$13.

"We find it impressive that Inovio first designed INO-4800 on January 10, within three hours of receiving the viral genetic sequence, and managed to complete preclinical studies and manufacture 3,000 human trial doses in roughly three months... we believe INO-4800 could be ready for a Phase 2 trial and available for emergency use by the end of 2020," they note.

Top Stock No. 2 – Moderna Inc. (MRNA)

We recommended Moderna Inc. on April 15, as it traded at \$34.52. Then, just last Wednesday, we highlighted it again at \$64.05. It's now up to \$86.50 and still running.

Moderna (MRNA) is racing to higher highs on news its vaccine produced COVID-19 antibodies in all 45 of its participants.



“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 (micrograms),” Tal Zaks, the chief medical officer at Moderna said, as quoted by CNBC.

“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” he added.

If the company sees further success, Phase II trials will begin shortly.

Phase III could begin shortly after that with thousands of healthy volunteers.

According to Bloomberg, “the mRNA technology being used by Moderna and several others relies on the body’s own cells to produce viral proteins. Once injected into the body, the RNA slips into human cells and tells them to make virus-like proteins, in this case the “spike” protein on the surface of the coronavirus. If the vaccine works, those proteins then trigger the body to generate protective antibodies.”

Top Stock No. 3 – Sorrento Pharmaceuticals (SRNE)

SRNE rocketed 158% higher last Friday on volume of 507.6 million shares, as compared to daily average volume of 14.8 million shares. However, it doesn’t appear the run is over just yet after it provided an upbeat assessment on its COVID-19 antibody experiment.



As reported by MarketWatch, “After four days of incubation, Sorrento said its STI-1499 antibody demonstrated 100% inhibition of the COVID-19 virus infection of healthy cells. The company said full results of the experiment will be soon submitted to a “peer-reviewed publication.”